Does Pacific Edge have a target on its back?

Does Pacific Edge have a target on its back?
Invested capital in Cxbladder makes for an 'attractive acquisition target' (Image: supplied)
Brent Melville
Cancer diagnostic company Pacific Edge could be ripe for a takeover, analysis by investment firm Bell Potter suggests.Bell Potter, the Australian adviser to Pacific Edge’s September listing on the ASX, kicked off coverage of the Dunedin-based company with a speculative buy recommendation this week, valuing it at A$1.10 ($1.19) a share. That’s an 18% premium to Tuesday’s ASX price of 93 Australian cents, and a firm advance on its NZX Tuesday close of 99 cents. Local investment house Jarden pegs the NZX target price at $1.1...

More Markets

Zespri lowers net profit guidance for current season
Primary Sector

Zespri lowers net profit guidance for current season

Downgrade comes following a reduction in forecast Zespri global supply (ZGS) volumes.

Fletcher Building's monthly power bill rises by millions
Infrastructure

Fletcher Building's monthly power bill rises by millions

The building giant says energy costs have risen by up to $3 million more each month.

Ebos well positioned to pursue growth opportunities
Markets

Ebos well positioned to pursue growth opportunities

The healthcare and animal care group's underlying net profit was up 7.7% on the year.

Sky TV financial results: after-tax profit of $49.2m
Markets

Sky TV financial results: after-tax profit of $49.2m

Sky TV has delivered a “solid” net after-tax profit of $49.2 million, a drop of 3.7% on its previous financial year in what it describes as difficult and challenging market conditions, which has seen its customer base fall to its lowest in five years.The result comes as the compa...